Olema Pharmaceuticals Inc. (NASDAQ:OLMA) is one of the best hot stocks to invest in. On October 8, Guggenheim initiated coverage of Olema Oncology with a Buy rating and $20 price target. The firm views Olema as the top biotech for selective estrogen receptor degrader/SERD breast cancer drugs. Guggenheim cited its palazestrant as the most promising drug in a$10 billion market. The company discovers and develops targeted therapies for breast cancer and beyond. A key highlight was the selection of a 90 mg o ...